期刊文献+

曲普瑞林治疗子宫内膜异位症应个体化 被引量:10

Clinical Study of Individualized Treatment of Triptorelin in Endometriosis
下载PDF
导出
摘要 目的:探讨曲普瑞林(商品名:达菲林)个体化治疗子宫内膜异位症(EMs)的必要性。方法:对34例卵巢子宫内膜异位囊肿剥除术后的患者进行前瞻性临床观察,辅助注射曲普瑞林3.75mg3~6个月,每28天1次。观察曲普瑞林治疗后的近期不良反应,尤其是异常阴道出血和潮热、盗汗症状,同时测定用药第0,7,21天血清卵泡刺激素(FSH)、黄体生成激素(LH)和雌二醇(E2)水平。结果:根据是否阴道异常出血将患者分成2组,用药第7天血清E2水平差异有统计学意义(Z=2.612,P=0.009)。E2水平与阴道出血的天数呈正相关(rs=0.587,P<0.05)。再根据是否出现严重潮热、盗汗将患者分成2组,发现用药第21天FSH水平和FSH/LH比值差异均有统计学意义(Z=2.247,P=0.025;Z=2.201,P=0.028)。FSH水平和FSH/LH比值均与潮热、盗汗的程度呈负相关(rs=-0.541,rs=-0.588,P<0.05)。结论:个体差异可能导致曲普瑞林治疗后内分泌变化和近期不良反应不同,应该实施个体化治疗。曲普瑞林注射后第7天的E2水平可以预测是否有异常阴道出血发生,第21天血清FSH水平或FSH/LH比值可以预测潮热、盗汗的严重程度,协助选择最佳治疗方案。 Objective: To study the necessarity of individualized treatment of Triptorelin (trade name Diphereline) in the patients with endometriosis. Methods: A prospective clinical study involving 31 patients who underwent chocolate cystectomy. These patients were administered Triptorelin 3.75 mg for 3 to 6 times, 28 days apart. We evaluated the symptoms of genital bleeding and hot flashes during Triptorelin treatment, as well as the levels of serum FSH, LH and estradiol at the first and third weekend after the start of treatment. Results: We divided all the patients into 2 groups according to the genital bleeding(i.e. the group of menstruation-like bleeding and the group of abnormal genital bleeding). Statistically difference of estradiol was found in the first weekend after the treatment between the 2 groups(Z=2.612, P=0.009). The estradiol was positively correlated to the days of genital bleeding (rs=0.587, P0.05). According to the severe hot flashes we divided the patients into 2 groups and found that the serum FSH and FSH/LH ratio was statistically difference in the 3 weekend after treatment(Z=2.247, P=0.025; Z=2.201, P=0.028). The serum FSH and FSH/LH ratio were inversely correlated to the degree of hot flashes(rs=-0.541, rs=-0.588, P0.05). Conclusions: These differences in the endocrinological changes in response to Triptorelin might be derived from the patient′s individual difference. The estradiol at the first weekend after the start of Triptorelin treatment can predict the abnormal genital bleeding. The serum FSH and FSH/LH ratio at the third weekend after the start of Triptorelin treatment can predict the degree of hot flashes and help us to choice the best treatment plan.
作者 李政 岳天孚
出处 《国际妇产科学杂志》 CAS 2011年第4期281-284,共4页 Journal of International Obstetrics and Gynecology
关键词 子宫内膜异位症 卵巢囊肿 促性腺素释放激素 曲普瑞林 Endometriosis Ovarian cysts Gonadotropin-releasing hormone Triptorelin
  • 相关文献

参考文献12

  • 1Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic corre- lates [J]- Obstet Gynecol, 1996,87(3):321-327.
  • 2Erickson GF. Physiologic basis of ovulation induction [J]. Semin Reprod Endoerinol, 1996, 14 ( 4): 287-297.
  • 3孙爱军,肖琳,周远征,李杰,丁西来,田秦杰,郁琦,何方方,郎景和.促性腺激素释放激素类似物治疗子宫内膜异位症是否需要个体化[J].生殖与避孕,2008,28(1):50-53. 被引量:19
  • 4李继俊译.临床妇科内分泌学与不孕[M].山东:山东科学技术出版社.2001:112.
  • 5Jacoby VL, Fujimoto VY, Giudice LC, et al. Racial and ethnic dis- parities in benign gynecologic conditions and associated surgeries [J]. Am J Obstet Gynecol, 2010, 202(6):514-521.
  • 6Takeuchi H, Kobori H, Kikuchi I, et al. A prospective randomized study comparing endoerinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis [J]. J Obstet Gynaecol Res, 2000, 26(5 ): 325-331.
  • 7Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis [J ]. Am J Obstet Gynecol, 1992, 166(2): 740- 745.
  • 8Divasta A, Laufer M, Gordon C. Preservation of bone mineral density in adolescents treated with GnRH aganists and add-back therapy for endametriosis [C]. Florida: North American Society for Pedi- atric and Adolescent Gynecalagy Annual Meeting Orlando, 2006: 136-137.
  • 9Fuldeore MJ, Marx SE, Chwalisz K, et al. Add-hack therapy use and its impact on LA persistence in patients with endometriosis [J]. Curr Med Res Opin, 2010, 26(3 ): 729-736.
  • 10刘德艳,顾美皎,舒家振,史玉霞,王常玉,韩志强.促性腺激素释放激素激动剂延长用药间隔治疗子宫内膜异位症和子宫腺肌病的疗效观察[J].中华妇产科杂志,2006,41(10):656-659. 被引量:25

二级参考文献14

  • 1郎景和.子宫内膜异位症的诊断与处理[J].现代妇产科进展,2005,14(1):5-8. 被引量:111
  • 2孙爱军,刘春梅,孙智晶,段洁,任立新.门诊更年期妇女相关症状、行为和知识状况的调查[J].中华全科医师杂志,2005,4(7):415-417. 被引量:13
  • 3Regidor PA,Regidor M,Schmidt M,et al.Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.Gynecol Endocrinol,2001,15:202-209.
  • 4Ling FW.Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis.Pelvic Pain Study Group.Obstet Gynecol,1999,93:51-58.
  • 5Rotondi M,Labriola D,Rotondi M,et al.Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis.Eur J Gynaecol Oncol,2002,23:523-526.
  • 6Broekmans FJ,Bernardus RE,Berkhout G,et al.Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation:decapeptyl CR.Gynecol Endocrinol,1992,6:153-161.
  • 7Kraus S,Naor Z,Seger R.Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor.Arch Med Res,2001,32:499-509.
  • 8Limonta P,Moretti RM,Marelli MM,et al.The biology of gonadotropin hormone-releasing hormone:role in the control of tumor growth and progression in humans.Front Neuroendocrinol,2003,24:279-295.
  • 9Millar RP,Lu ZL,Pawson AJ,et al.Gonadotropin-releasing hormone receptors.Endocr Rev,2004,25:235-275.
  • 10Vercellini P,Crosignani PG,Fadini R,et al.A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.Br J Obstet Gynaecol,1999,106:672-677.

共引文献42

同被引文献77

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部